Medexus Announces Strong Fiscal Q2 2027 Results Driven By Record Product-Level Performance of GRAFAPEX (Treosulfan) for Injection

Medexus posts record quarterly results, driven by GRAFAPEX growth and improved profitability.

What the company is saying

Medexus Pharmaceuticals frames this update as a record-setting quarter, highlighting new highs in net revenue ($29.1 million), Adjusted EBITDA ($5.1 million), operating income ($2.4 million), and net income ($0.8 million) since the commercial launch of GRAFAPEX. CEO Ken d'Entremont emphasizes GRAFAPEX's strong market adoption in the United States allo-HSCT space and reiterates fiscal 2027 product-level net revenue guidance of $30 million to $32 million. The company signals confidence in its expanded commercialization strategy, including increased field force investment, and projects long-term GRAFAPEX revenue potential of $100 million to $175 million annually within five years. CFO Brendon Buschman points to a Net Debt to Adjusted EBITDA ratio of 0.97x and ongoing operating cash flow generation as evidence of financial strength. The update also covers progress on UM171 Cell Therapy in Canada, ongoing patent litigation for Rasuvo, and the impact of generic competition on Canadian products. The tone is confident, with management attributing year-over-year gains to GRAFAPEX and IXINITY growth, while acknowledging offsetting factors such as the expiry of Rupall exclusivity.

What the data suggests

The disclosed numbers confirm a clear upward trajectory: net revenue rose 17.6% year-over-year for the quarter and 16.9% for the half, with GRAFAPEX contributing $5.7 million and $10.6 million in product-level net revenue for the three- and six-month periods, respectively. GRAFAPEX's underlying patient demand grew 16% sequentially and 156% year-over-year, supporting management's claims of strong adoption. Adjusted EBITDA increased to $5.1 million for the quarter, up $0.7 million, while operating income more than doubled to $2.4 million. Net income swung from a $0.3 million loss to a $0.8 million profit. Cash provided by operating activities was $5.4 million for the quarter, and available liquidity stood at $8.4 million, though the company now has no available credit under its revolving facility. Gross margin remained stable at 55.9%, and Adjusted Gross Margin was 64.0%. The company expects GRAFAPEX Adjusted Gross Margin to ultimately reach 85%. IXINITY and Rasuvo both saw double-digit demand growth, while Metoject and Rupall volumes declined due to generic competition. The data is comprehensive, with all major claims substantiated by period-over-period comparisons and product-level detail.

Analysis

The announcement's tone is positive but proportionate to the company's actual, measurable progress. Medexus reports record quarterly results in net revenue, Adjusted EBITDA, operating income, and net income, all supported by detailed numerical disclosures and clear period-over-period improvement. The majority of key claims are realised facts, with only a minority of forward-looking statements (notably, long-term GRAFAPEX revenue targets and UM171 Cell Therapy timelines). The forward-looking claims are clearly separated from realised results and do not dominate the narrative. There is no evidence of narrative inflation or exaggerated language; the company provides granular data on product-level performance, investments, and cash flow. Capital outlays (e.g., IXINITY manufacturing upgrade) are modest relative to cash flow and are not paired with speculative, long-dated returns. The gap between narrative and evidence is minimal.

Risk flags

• ●GRAFAPEX revenue targets for fiscal 2027 ($30 million to $32 million) require continued acceleration in adoption and repeat orders; any slowdown in uptake or changes in reimbursement could result in a miss versus guidance.
• ●The company's liquidity position is adequate at $8.4 million in cash, but the loss of available credit under the revolving facility reduces financial flexibility if cash flow weakens or unexpected costs arise.
• ●Generic competition is materially impacting Canadian products: Rupall patient unit demand fell 25.7% and 27.4% for the quarter and half, and Metoject demand declined 3%, which could pressure overall portfolio margins and offset gains from GRAFAPEX and IXINITY.
• ●Long-term GRAFAPEX revenue and margin targets (up to $175 million annual revenue and 85% Adjusted Gross Margin) are ambitious and depend on factors such as market expansion, pricing, and competitive dynamics that may not materialize as projected.
• ●UM171 Cell Therapy commercialization is several years away (2028–2031), with regulatory and clinical milestones yet to be achieved, introducing significant execution and timing risk for this pipeline asset.

Bottom line

Medexus delivered record quarterly financials, with GRAFAPEX driving revenue and profit growth and supporting a positive operating cash flow trend. The company's guidance for GRAFAPEX in fiscal 2027 ($30 million to $32 million) is credible given current adoption rates, but will require sustained momentum in the coming quarters. Liquidity is solid but tighter than before, as the company now relies solely on cash reserves with no undrawn credit. Portfolio risks remain from generic erosion in Canada, which could dampen overall margin expansion. Long-term targets for GRAFAPEX and pipeline assets like UM171 Cell Therapy are promising but distant and contingent on successful execution. The most important takeaway is that Medexus's core US business is performing strongly, but future upside depends on both maintaining GRAFAPEX growth and navigating competitive and regulatory hurdles in other markets.

Announcement summary

(TSX:MDP) (OTCQX:MEDXF) Medexus Pharmaceuticals reported operating and financial results for its second fiscal quarter ended September 30, 2026 (fiscal Q2 2027). The company achieved quarterly records in net revenue, Adjusted EBITDA, operating income, and net income since the commercial launch of GRAFAPEX in fiscal Q4 2025. Product-level net revenue from GRAFAPEX was $5.7 million for the three months and $10.6 million for the six months ended September 30, 2026. GRAFAPEX personnel and infrastructure investments were $3.8 million and $7.0 million for the same periods, with cost of sales of products (before amortization) at $0.7 million and $1.3 million. Medexus expects GRAFAPEX product-level net revenue for fiscal year 2027 to be between $30 million and $32 million, and continues to target annual product-level net revenue of $100 million to $175 million within five years of commercial launch. Net revenue for the three- and six-month periods ended September 30, 2026 was $29.1 million and $57.7 million, up $4.4 million and $8.3 million from $24.7 million and $49.4 million in the prior year periods, primarily due to increased revenue from GRAFAPEX, IXINITY, and Rasuvo. Adjusted EBITDA was $5.1 million and $9.8 million, up $0.7 million and $2.0 million from $4.4 million and $7.8 million in the prior year periods. Operating income was $2.4 million and $4.6 million, up $1.1 million and $2.3 million from $1.4 million and $2.2 million in the prior year periods. Gross margin was 55.9% and 55.8%, and Adjusted Gross Margin was 64.0% and 63.9% for the three- and six-month periods, respectively. Net income was $0.8 million and $1.4 million, compared to a net loss of $0.3 million and net income of $0.2 million in the prior year periods. Available liquidity as of September 30, 2026 was $8.4 million, consisting of cash and cash equivalents of $8.4 million and no available credit under the revolving facility (compared to $6.5 million cash and $2.5 million credit at March 31, 2026). Cash provided by operating activities was $5.4 million and $4.7 million for the three- and six-month periods, compared to $3.3 million and $7.3 million in the prior year periods. Net Debt to Adjusted EBITDA was 0.97x as of September 30, 2026. Underlying patient demand for GRAFAPEX was $5.6 million for fiscal Q2 2027, up 16% from $4.8 million in fiscal Q1 2027 and up 156% from $2.1 million in fiscal Q2 2026. Since launch, total wholesaler purchases of GRAFAPEX have exceeded total demand by $1.4 million, resulting in about one month of inventory on hand at September 30, 2026. Medexus expects the annual product-level Adjusted Gross Margin of GRAFAPEX will ultimately be approximately 85%. Patient unit demand for IXINITY in the US increased by 12% over the trailing 12-month period ended September 30, 2026. In fiscal Q3 2026, Medexus entered into an agreement with its contract manufacturer for a $4.0 million manufacturing process upgrade for IXINITY (plus $2.0 million for a test batch), with $1.4 million paid in fiscal year 2026 and no amounts paid in fiscal year 2027 to date. In June 2026, Medexus secured exclusive Canadian rights to commercialize UM171 Cell Therapy (Zemcelpro®/dorocubicel) in a license and supply deal with ExCellThera and Cordex Biologics. Cordex will manage a phase 3 clinical trial as a post-authorization measure for the product's conditional marketing authorization in Europe. Medexus will sponsor the new drug submission seeking Health Canada approval of UM171 Cell Therapy, with commercialization in Canada not expected before calendar year 2028 or possibly 2031. Patient unit demand for Rasuvo in the US increased by 15% over the trailing 12-month period ended September 30, 2026. In July 2026, Medexus and medac filed a patent infringement lawsuit regarding a proposed generic version of Rasuvo, which remains ongoing. Patient unit demand for Metoject in Canada decreased by 3% over the trailing 12-month period, attributed to generic competition. Rupall's market exclusivity in Canada expired in January 2025, and patient unit demand decreased by 25.7% and 27.4% for the three- and six-month periods ended September 30, 2026 compared to the prior year periods.

Disagree with this article?